Literature DB >> 2143719

Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids.

F Z Stanczyk1, S Roy.   

Abstract

There is limited information on the metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids. Both levonorgestrel and norethindrone undergo extensive reduction of the alpha, beta-unsaturated ketone in ring A. Levonorgestrel also undergoes hydroxylation at carbons 2 and 16. The metabolites of both compounds circulate predominantly as sulfates. In urine, levonorgestrel metabolites are found primarily in the glucuronide form, whereas norethindrone metabolites are present in approximately equal amounts as sulfates and glucuronides. Of the progestogens structurally related to norethindrone, norethindrone acetate, ethynodiol diacetate, norethindrone enanthate, and perhaps lynestrenol, undergo rapid hydrolysis and are converted to the parent compound and its metabolites. There is no convincing evidence that norethynodrel is converted to norethindrone. Of the progestogens structurally related to levonorgestrel, it appears that neither desogestrel nor gestodene are transformed to the parent compound. However, there is evidence that norgestimate can be, at least partly, converted to levonorgestrel. Further studies on the metabolism of these progestogens are required before we can understand their mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143719     DOI: 10.1016/0010-7824(90)90093-b

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.

Authors:  Jagdev Sidhu; Sarah Job; Sunita Singh; Richard Philipson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

5.  Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.

Authors:  Yi Jin; Ling Duan; Mo Chen; Trevor M Penning; Helenius J Kloosterboer
Journal:  J Steroid Biochem Mol Biol       Date:  2011-12-28       Impact factor: 4.292

Review 6.  Role of CYP3A in Oral Contraceptives Clearance.

Authors:  Nan Zhang; Jihong Shon; Myong-Jin Kim; Chongwoo Yu; Lei Zhang; Shiew-Mei Huang; LaiMing Lee; Doanh Tran; Li Li
Journal:  Clin Transl Sci       Date:  2017-10-06       Impact factor: 4.689

7.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

Review 8.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

9.  Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.

Authors:  Alison Edelman; Myrna Munar; Miriam R Elman; Dennis Koop; Ganesh Cherala
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

10.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.